Surrozen, Inc.

Equities

SRZN

US86889P2083

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 01:12:49 2024-04-29 pm EDT			5-day change	1st Jan Change
9.425 ^USD	+4.96%		+1.89%	+0.27%

Apr. 10	Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 08	Surrozen Insider Bought Shares Worth $2,999,994, According to a Recent SEC Filing	MT

Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

April 10, 2024 at 04:39 pm EDT

Surrozen, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 43.04 million compared to USD 36 million a year ago. Basic loss per share from continuing operations was USD 21.33 compared to USD 15.56 a year ago.

Latest news about Surrozen, Inc.

Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 10	CI
Surrozen Insider Bought Shares Worth $2,999,994, According to a Recent SEC Filing	Apr. 08	MT
Surrozen, Inc. announced that it has received $17.500008 million in funding from The Column Group, LLC, Ra Capital Management, Inc.	Apr. 03	CI
Surrozen Provides Update on the Phase 1A Clinical Trial of SZN-043 in Healthy Volunteers and Patients with Cirrhosis	Apr. 01	CI
Surrozen, Inc. announced that it expects to receive $17.549999 million in funding	Mar. 31	CI
Surrozen, Inc. Appoints Charles Williams to the Concurrent Position of Chief Operating Officer	Feb. 07	CI
Sector Update: Health Care Stocks Softer Late Thursday Afternoon	Jan. 18	MT
Sector Update: Health Care Stocks Weaker Thursday Afternoon	Jan. 18	MT
Surrozen to Stop Inflammatory Bowel Disease Clinical Trial; Shares Fall	Jan. 18	MT
Surrozen, Inc. Provides Corporate Update on Clinical Programs	Jan. 18	CI
Surrozen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Surrozen, Inc. Expects to Initiate A Phase 1a Clinical Trials for SZN-043 and SZN-1326 in Moderate to Severe Alcoholic Hepatitis	Nov. 08	CI
Surrozen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Surrozen, Inc. Announces Management Changes	23-07-19	CI
Surrozen, Inc.(NasdaqCM:SRZN) dropped from Russell Microcap Index	23-06-23	CI
Surrozen, Inc.(NasdaqCM:SRZN) dropped from Russell Microcap Value Index	23-06-23	CI
Surrozen, Inc.(NasdaqCM:SRZN) dropped from Russell 3000E Value Index	23-06-23	CI
Surrozen, Inc.(NasdaqCM:SRZN) dropped from Russell 3000E Index	23-06-23	CI
Surrozen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Surrozen, Inc. Announces Appointment of Eric Bjerkholt to its Board	23-04-05	CI
Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-22	CI
Transcript : Surrozen, Inc., Q4 2022 Earnings Call, Mar 22, 2023	23-03-22
Transcript : Surrozen, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-12-2023 07:30 AM	23-01-12
Top Premarket Decliners	22-12-27	MT
Weaker-Than-Expected Retail Sales, Hawkish Fed Send US Stock Futures Sharply Lower	22-12-15	MT

Chart Surrozen, Inc.

Duration

Period

More charts

Company Profile

Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company's lead product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt or R-spondin proteins, which are involved in activation and enhancement of the Wnt pathway. Its two technologies, Surrozen Wnt signal Activating Protein (SWAP) and Surrozen Wnt signal Enhancers Engineered for Tissue Specificity (SWEETS), enable it to potently and selectively modulate Wnt signaling through the generation of Wnt and R-spondin mimetics. SWAP molecules are designed to mimic the activity of naturally occurring Wnt proteins. SWEETS molecules are designed to amplify the bodyâs response to naturally occurring Wnt proteins. Its product candidates include SZN-1326, SZN-043 and SZN-413.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

8.98 USD

Average target price

33 USD

Spread / Average Target

+267.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SURROZEN, INC.	+0.27%	28.72M
IQVIA HOLDINGS INC.	+2.42%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+11.98%	41.34B
CELLTRION, INC.	-8.83%	26.59B
ICON PUBLIC LIMITED COMPANY	+7.08%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-22.60%	18.12B
MEDPACE HOLDINGS, INC.	+30.65%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.90%	11.76B
UNITED THERAPEUTICS CORPORATION	+9.24%	11B

Other Biotechnology & Medical Research